Frank Karbe - 18 Dec 2023 Form 4 Insider Report for Better Therapeutics, Inc.

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: N/A
Reported as of: 18 Dec 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Dec 2023, 17:13:55 UTC
Prior SEC filing: 31 Jul 2023
Next SEC filing: 24 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Leslie Miller, Attorney-in-fact

Key filing fact

Frank Karbe filed Form 4 for Better Therapeutics, Inc. on 20 Dec 2023.

Key facts

This page summarizes Frank Karbe's Form 4 filing for Better Therapeutics, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Dec 2023, 17:13.

Change

Previous filing in this sequence was filed on 31 Jul 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BTTX transaction

Common Stock

Award

Transaction value: $0
Shares: +62,500
Change %: +13%
Price: $0.000000
Shares after: 526,516
Date: 18 Dec 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting person was awarded 62,500 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on June 1, 2024.

Footnote F2

Includes 34,587 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2023.